Cargando…

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Žučenka, Andrius, Vasilevska, Dominika, Daukėlaitė, Guoda, Trociukas, Igoris, Pečeliūnas, Valdas, Pileckyte, Regina, Griškevičius, Laimonas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429772/ http://dx.doi.org/10.1097/01.HS9.0000969204.07443.aa

Ejemplares similares

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
por: Žučenka, Andrius, et al.
Publicado: (2023)

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION
por: Liang, Chen, et al.
Publicado: (2023)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly
por: Saburi, Masuho, et al.
Publicado: (2023)

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
por: Maneikis, Kazimieras, et al.
Publicado: (2021)

Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan
por: Maneikis, Kazimieras, et al.
Publicado: (2020)

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
por: Chew, Serena, et al.
Publicado: (2020)

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020)

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
por: McCall, David, et al.
Publicado: (2021)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)

Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
por: Pileckyte, Regina, et al.
Publicado: (2019)

HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2019)

Corrigendum to “HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia”
por: Vitkevičienė, Aida, et al.
Publicado: (2020)

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD(+) acute myeloid leukemia
por: Ueno, Yoko, et al.
Publicado: (2019)

Evaluation of hypereosinophilia in a case of FLT3-mutant acute myeloid leukemia treated with gilteritinib
por: Martinez-Gutierrez, Leslie N., et al.
Publicado: (2023)

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2020)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3(mut) AML
por: Terao, Toshiki, et al.
Publicado: (2022)

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
por: Mori, Masamichi, et al.
Publicado: (2017)

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
por: Hosono, Naoko, et al.
Publicado: (2021)

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
por: Bocchia, Monica, et al.
Publicado: (2022)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
por: Zhang, Yvyin, et al.
Publicado: (2023)

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2021)

Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
por: Katagiri, Seiichiro, et al.
Publicado: (2023)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients
por: Molica, Matteo, et al.
Publicado: (2023)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
por: Ha, You Na, et al.
Publicado: (2020)

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2020)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
por: Smith, Catherine C., et al.
Publicado: (2022)

FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
por: Blackmon, Amanda, et al.
Publicado: (2022)

Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
por: Sugamori, Haruko, et al.
Publicado: (2022)

Diagnostic Challenge of Necrotizing Soft Tissue Infection in a Patient With B Lymphocytic Leukemia
por: Sadauskas, Andrius, et al.
Publicado: (2020)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
por: Perl, Alexander E., et al.
Publicado: (2022)

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
por: Wu, Shuangshuang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ok35v2u2a3s689rvsd6i88k4g9